In line with this, a study by Spilman et al.70demonstrated that chronic treatment with rapamycin, an mTOR inhibitor, for 13 weeks could reduce Aβ42 levels in the brains of a transgenic mouse model of AD. This evidence concerns the gene MTOR and Alzheimer disease.